First biomolecular condensates research collaboration to identify drug candidates related to insulin resistance and diabetic complications Dewpoint is eligible to receive up to $55 million near term and up to $690 million of clinical, commercial and sales milestones plus royalties across…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.